Latest News and Press Releases

Longeveron to report 3Q25 financial results and host investor/analyst call/webcast on Tuesday, November 4, 2025 after close of US financial markets.

Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS.

Longeveron will participate in the 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 in New York City.

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors.

Longeveron hosting partnering discussions for its Alzheimer's disease stem cell therapy program at Cell & Gene Meeting on the Mesa.

Longeveron BOD appoints Interim CEO and Executive Chairman of BOD. Board plans to conduct a national search to identify a permanent CEO.

Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...

Longeveron announces closing of up to $17.5 million public offering. Proceeds to support potential BLA readiness activities, among other items.

Longeveron announces the pricing of a public offering of common stock and warrants.